Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

ALGN · Q2 2025 Earnings

Align Technology

Reported July 30, 2025

30-second summary

30-second take: Revenue fell 1.6% YoY to $1.01B as Clear Aligner volume eked out just +0.3% growth and Clear Aligner revenue dropped 3.3%, with management pinning weakness on North America, France, and Germany. Align is now cutting costs — restructuring charges of $150–170M land in H2 — and lowered the FY25 frame to "flat to slightly up" revenue with non-GAAP operating margin "slightly above 22.5%". The story has shifted from category growth to defense; 2025 is the fourth straight year of declining orthodontic case starts, and management's tone confirms this is being treated as structural, not cyclical.

Headline numbers

EPS

Q2 FY2025

$2.49

Revenue

Q2 FY2025

$1.01B

-1.6% YoY

Gross margin

Q2 FY2025

69.9%

Operating margin

Q2 FY2025

16.1%

Key financials

Q2 FY2025

Metric	Q2 FY2025	YoY
Revenue	$1.01B	-1.6%
EPS	$2.49	—
Gross margin	69.9%	—
Operating margin	16.1%	—

Guidance

Prior quarter data unavailable — comparison not possible.

Segment KPIs

Q2 FY2025

Segment	Q2 FY2025	YoY
Clear Aligner	$0.805B	-3.3%
Imaging Systems and CAD/CAM Services	$0.208B	+5.6%

Other KPIs

Q2 FY2025

Segment	Q2 FY2025
Clear Aligner Volume (thousands of cases)	644.4
Clear Aligner Volume YoY Growth	+0.3%
Revenue Per Case Shipment	$1,250
Invisalign Trained Doctors Active	86,250
Doctor Utilization Rate (cases per doctor)	7.5
Non-GAAP Operating Margin	21.3%
Non-GAAP Gross Margin	70.5%
Cash and Cash Equivalents	$901.2M

Management tone

This quarter's posture is defensive in a way that does not square with how Align has historically framed itself. Three shifts stand out.

The growth narrative has been replaced with a restructuring narrative. Management's prior operating model centered on commercial investment to expand the category; this quarter it announced workforce reductions, business group realignment, and manufacturing footprint optimization, with $150–170M of one-time charges in H2. The framing: "We are evaluating actions to reduce costs and thoughtfully manage our investments...realign certain business groups and reduce our global workforce...optimize our manufacturing footprint and dispose of certain manufacturing capital assets." This is not a growth company optimizing the margin tail — this is a company conceding the top line is not coming back on the prior trajectory and resizing accordingly.

The diagnosis of weakness has broadened from "patient demand" to "patient demand plus doctor behavior plus financing." That is a meaningfully worse problem. Management said "You have others...that doctor because of economics puts that patient that's in their chair into wires and brackets versus maybe they might even came in asking for Invisalign." When patients walk in asking for the product by name and leave with the competing legacy product because the doctor's economics favor it, that is a pricing/positioning issue, not just a macro one. Calling out "2025 marks the fourth consecutive year of orthodontic starts being down" makes the structural read explicit.

The confidence posture itself is contradictory. Management said "We're confident in our ability to adapt and lead...While we believe in the macroeconomic uncertainty will likely persist in the near future" — simultaneously asserting conviction and forecasting prolonged uncertainty. Pair that with hedging language across the outlook ("Subject to, we expect", "Assuming no circumstances occur beyond our control") and the result is a management team telegraphing that it does not know when the bottom is in.

Recurring themes management leaned on this quarter:

Macro headwinds and consumer reluctance overriding brand strengthRestructuring and operational efficiency as near-term strategic priorityStrong underlying patient interest masking conversion challengesRegional divergence with North America and Western Europe most impactedProduct mix shift toward lower-priced offerings and non-comprehensive casesGP channel resilience relative to orthodontic channel pressure

Risks management surfaced:

Continued US tariff volatility and inflation impact on consumer confidencePatient financing constraints and reduced access to orthodontic creditShift of patient volume from clear aligners to traditional wires and brackets in orthodontic practicesReduced capital equipment spending by practices due to lower patient trafficPotential continued macroeconomic uncertainty and spending hesitancy

What to watch into next quarter

Clear Aligner volume growth turning negative. Q2 came in at +0.3% YoY with FY guided to low-single digits. If Q3 volume prints negative YoY, the FY guide is at risk and the "structural vs cyclical" debate tilts decisively structural.

Revenue per case trajectory. $1,250 this quarter with ASPs guided down YoY on non-comprehensive mix shift. Watch whether the mix shift accelerates — a further step-down would mean even flat volumes don't produce flat revenue.

Q3 revenue vs $975M midpoint. Guide implies -3.7% QoQ; a miss against that would mean even the reset bar was too high.

Restructuring charge containment within $150–170M. Overruns or scope expansion in Q3 would signal the cost program is larger than initially scoped.

North America and Western Europe (France, Germany) stabilization. Management identified these three as the concentrated source of weakness; "rest of world performed at expectation." Continued isolation to these geographies would be a better read than spread.

FY26 ≥100bps operating margin improvement commitment. This is the only forward anchor management offered beyond 2025. Watch for any walk-back in Q3 or Q4 commentary.

Sources

Align Technology Q2 2025 earnings press release, July 30, 2025 — https://www.sec.gov/Archives/edgar/data/1097149/000109714925000055/algn-q225earningspressrele.htm

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.